NDAORALTABLET
Approved
Jan 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
TASMAR (tolcapone) by Bausch + Lomb is catechol o-methyltransferase inhibitors [moa]. First approved in 1998.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TASMAR (tolcapone) is a Catechol O-Methyltransferase (COMT) inhibitor oral tablet approved in 1998 for Parkinson's Disease and investigated for transthyretin amyloidosis, ADHD, and alcohol use disorder. It works by inhibiting COMT enzyme activity to extend dopamine availability in the central nervous system. The drug addresses motor fluctuations and off-periods in Parkinson's patients receiving levodopa therapy.
$0.201MPart D
LOE ApproachingDeclining
Minimal commercial activity with only 13 Part D claims in 2023 signals a niche product with limited team growth potential; brand likely focused on defense or specialty positioning.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)
Started Oct 2018
10 enrolled
Transthyretin AmyloidosisAmyloidosis, Leptomeningeal, Transthyretin-Related
A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone
Started Jun 2018
12 enrolled
Healthy Volunteers
Career Relevance
TASMAR has zero linked job openings and minimal commercial footprint, indicating the product attracts very limited career interest at Bausch + Lomb. Professionals seeking stable, growth-oriented roles should evaluate other Bausch + Lomb assets or competitor products in the neurology space.
Worked on TASMAR at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.